Radiopharmaceuticals for Targeted Tumor Diagnosis and Therapy


  • Robert Waibel
  • Ilse Novak-Hofer
  • Roger Schibli
  • Peter Bläuenstein
  • Elisa Garcia-Garayoa
  • Rolf Schwarzbach
  • Kurt Zimmermann
  • Raimo Pellikka
  • Olga Gasser
  • Alain Blanc
  • Matthias Brühlmeier
  • P. August Schubiger



Nuclide therapy, Pharmaceutical chemistry, Radioimmunotherapy, Radiopharmaceuticals, 99mtc, Tumor imaging


Radiopharmaceutical research and development is carried out by the Center for Radiopharmaceutical Science as part of the PSI Life Science Department, the Department of Applied BioSciences at the Swiss Federal Institute of Technology Zürich and the University Hospital Zürich. The common theme is the search for radioactive-labeled tracer molecules, which bind to specific targets in the body. Such radiopharmaceuticals are applied either systemically into the blood stream or locally to patients. Due to their specific molecular binding properties combined with the emitted radiation, they can be used for non-invasive imaging of tumors and the destruction of tumor cells. In this first of two articles, we will present exemplified topics from the research activities of the groups involved with tumor targeting.




How to Cite

R. Waibel, I. Novak-Hofer, R. Schibli, P. Bläuenstein, E. Garcia-Garayoa, R. Schwarzbach, K. Zimmermann, R. Pellikka, O. Gasser, A. Blanc, M. Brühlmeier, P. A. Schubiger, Chimia 2000, 54, 683, DOI: 10.2533/chimia.2000.683.



Scientific Articles